ScripPublic biopharmaceutical company valuations have taken a sharp turn into the red in the US during the past month, plunging the industry’s market for initial public offering into a drought. This trend
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genexine, KGBio Ink $1.1bn License Pact